Generic molecule: apixaban
Companies: Pfizer, Bristol-Myers Squibb
Approval date: Dec. 28
The scoop: Days before the year's end, FDA approved Eliquis--and 3 months before the drug's PDUFA date. The joint venture by Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) is a blood thinner meant for reducing risk of stroke and blood clots in patients with non-valvular atrial fibrillation. Twice-delayed by the FDA, Eliquis's approval is predated by two other warfarin alternatives: Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa.